US Markets
AZN

AstraZeneca, Oxford allowed to resume COVID-19 vaccine trial in U.S. - WSJ

Credit: REUTERS/DADO RUVIC

Federal health regulators have decided to allow the resumption of U.S. studies of a leading COVID-19 vaccine candidate from AstraZeneca Plc and the University of Oxford, the Wall Street Journal reported on Friday, citing a person familiar with the matter and materials reviewed by it.

Adds background

Oct 23 (Reuters) - Federal health regulators have decided to allow the resumption of U.S. studies of a leading COVID-19 vaccine candidate from AstraZeneca Plc AZN.L and the University of Oxford, the Wall Street Journal reported on Friday, citing a person familiar with the matter and materials reviewed by it.

Reuters on Tuesday had reported that the U.S. Food and Drug Administration had completed its review and that the trial in the country was set to resume as early as this week, citing four sources familiar with the situation.

Trials in the United Kingdom, Brazil and South Africa resumed last month even as the U.S. health regulator continued its investigation into the case.

AstraZeneca's vaccine is being developed along with researchers at Oxford University.

(Reporting by Munsif Vengattil; Editing by Maju Samuel and Anil D'Silva)

((munsif.vengattil@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More